Bulletin
Investor Alert

Topics

Hepatitis

12:44 p.m. April 30, 2021 - Barrons.com
Two Biotechs Make Their Market Debut. One Falls Below Its Offer Price, the Other Ends Nearly Flat. Vaccitech, the co-inventor of the AstraZeneca vaccine, is a broken deal. Werewolf Therapeutics, which is working on cancer treatments, closes near its $16 offer price.
11:59 a.m. April 30, 2021 - By Michael Brush
'Drugs from bugs' --- biotech companies are mining the gut microbiome to treat difficult diseasesThe body's so-called germ squad in the gut can be tweaked, treating diseases including autism and Parkinson's disease.
2:59 p.m. April 29, 2021 - Barrons.com
What Ails Gilead's Sales Sales of the company's existing products weren't what some investors hoped.
4:52 a.m. April 26, 2021 - Barrons.com
A Key Player in Covid Vaccines Whose Stock You Can’t Trade—Yet One investor thinks the U.S. shares of China’s Sinovac could rise sixfold once a dispute is resolved and a trading suspension is lifted.
2:55 a.m. April 26, 2021 - Barrons.com
Buy Moderna Stock. It’s More Than a One-Hit Wonder. The drugmaker has the cash and the messenger RNA platform to drive years of strong growth. And for a biotech, it’s inexpensive.
4:16 a.m. April 5, 2021 - Barrons.com
BioNTech Has Surged on Covid Vaccine. Its Next Big Hit Might Take a While. CEO Ugur Sahin says his goal has been to make the biotech the next Amgen or Genentech.
11:05 a.m. March 29, 2021 - Barrons.com
uniQure Stock Is Higher After Investigators Conclude Its Gene Therapy Treatment Was Unlikely to Have Caused a Patient's Cancer Regulators froze uniQure's trial of its gene therapy for hemophilia in December when one of the 54 treated patients developed liver cancer.
4:28 a.m. March 24, 2021 - Barrons.com
You Can Buy a Tesla With Bitcoin Now Intel’s new CEO doubles down on chip manufacturing, positive news from Covid-19 treatments, GameStop earnings miss estimates, and other news to start your day.
8:42 a.m. March 23, 2021 - Barrons.com
Pfizer Will Test a Pill to Kill the Covid-19 Virus The experimental drug inhibits enzymes essential to replication, which is how many successful antiviral HIV and hepatitis C drugs work.
5:17 a.m. March 23, 2021 - Barrons.com
Regeneron Stock Climbs on Positive Covid-19 Antibody Data A Phase 3 trial showed a 70% drop in hospitalization or death for high-risk non-hospitalized patients, the latest in a string of positive results in studies of antibody treatments.
4:15 a.m. March 17, 2021 - MarketWatch
Startup behind AstraZeneca vaccine raises millionsLONDON -- The Oxford startup behind AstraZeneca PLC's Covid-19 vaccine has raised $168 million in new funding, which it plans to use to adopt its vaccine technology for the treatment of other diseases.
2:41 p.m. March 7, 2021 - MarketWatch
IPO for Oxford COVID-19 vaccine startup in perilA startup behind the Covid-19 vaccine developed by the University of Oxford and AstraZeneca PLC is planning an initial public offering that backers hope will be the biggest market debut of an Oxford spinoff in years.
5:29 a.m. Feb. 17, 2021 - Barrons.com
Vir and GSK Will Collaborate on Flu Therapy GlaxoSmithKline and Vir Biotechnology will collaborate to develop the same type of treatments for flu that they have made for Covid-19.
2:00 a.m. Feb. 12, 2021 - Barrons.com
Let Employers Mandate Vaccines Requiring a Covid-19 vaccination is like requiring hard hats or handwashing. Employers have the right to create a safe workplace.
4:30 p.m. Jan. 28, 2021 - Barrons.com
Qualtrics, Agrify Surge in Market Debuts. Ortho Clinical and Vinci Fall Below IPO Prices. The companies make their entrance at a boom time for initial public offerings, with January on track to be the biggest opening month for new stocks in over 20 years.
6:08 a.m. Jan. 27, 2021 - Barrons.com
Vir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again The newly announced trial is the first effort to combine Covid-19 antibody therapies developed by different companies.
11:23 a.m. Jan. 6, 2021 - MarketWatch.com
Why France's blundering COVID vaccination campaign is seen as a Macron fiasco and failure of 'ruling elites'Only a few hundred French citizens have received a COVID-19 shot in the week since vaccines began to be rolled out in the European Union.
11:37 p.m. Dec. 23, 2020 - MarketWatch.com
Getting COVID-19 may protect you be protected against future infections, two new studies indicateThe results bode well for vaccines, which provoke the immune system to make antibodies — substances that attach to a virus and help it be eliminated.
5:21 p.m. Dec. 11, 2020 - Barrons.com
Coach and Kate Spade Will Drive Tapestry Stock Higher And analysts report on Fiserve, Liberty Braves Group, and three other companies.
4:17 a.m. Dec. 10, 2020 - By Ciara Linnane
Gilead to acquire Germany's MYR GmbH for EUR1.15 billion in cash Gilead Sciences Inc. said Thursday it has agreed to acquire MYR GmbH, a German biotech, for 1.15 billion euros ($1.39 billion) in cash, plus a potential future milestone payment of up to 300 million euros. The milestone payment will be made upon FDA approval of MYR's hepcludex, a treatment for chronic HDV infection in adults with compensated liver disease that has won conditional approval from the European Medicines Agency. HDV is the most severe form of viral hepatitis. "Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP," Gilead said in a statement. "It is the first and currently the only medicine conditionally approved for HDV by the EMA, and MYR anticipates submission for accelerated approval in the United States in the second half of 2021." The drug has both orphan drug and breakthrough therapy designations from the FDA. Gilead is expecting the deal to enhance revenue, be neutral to EPS in the first two years and then modestly accretive. Gilead shares were slightly higher premarket, but have fallen 6% in the year to date, while the SPDR S&P Biotech ETF has gained 44% and the S&P 500 has gained 13.7%.
11:12 a.m. Dec. 9, 2020 - MarketWatch.com
Children probably won't get a COVID-19 vaccine before the next school year --- here's whyClinical trials for those 12 and older are just starting, and there haven't been any yet for those under 12.
6:11 a.m. Dec. 4, 2020 - Barrons.com
Vaccines and Approved Antibodies Dim Vir Biotechnology’s Covid Opportunity, Analyst Says Competitors have already gotten emergency use authorizations from regulators and booked orders for their antibody treatments.
8:40 a.m. Nov. 25, 2020 - Associated Press
Argentine soccer great Diego Maradona dies at 60 Argentina’s president declared three days of national mourning for Maradona on WednesdayDiego Maradona, the Argentine soccer great who was among the best players ever and who led his country to the 1986 World Cup title before later struggling with cocaine use and obesity, has died. He was 60.
5:29 p.m. Nov. 1, 2020 - Barrons.com
Chinese Lender Lufax Raises $2.36 Billion in IPO. It’s a Broken Deal. Shares of company backed by Ping An Insurance closed below the IPO price.
9:22 a.m. Oct. 29, 2020 - MarketWatch.com
COVID-19 immunity may only last a few months after infection, study indicatesResearchers find that the number of people in England with antibodies fell by 26% in the space of three months, though there is not yet scientific consensus on the longevity of COVID-19 antibodies.
2:06 p.m. Oct. 28, 2020 - Barrons.com
Gilead Sciences Benefits From Its Initial Quarter of Remdesivir Sales The antiviral remdesivir came just in time for Covid-19 patients and for its developer, Gilead Sciences.
3:17 p.m. Oct. 23, 2020 - Barrons.com
Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers. Until vaccines end the Covid pandemic, analysts expect billions of dollars in annual sales for treatments and other remedies.
12:22 p.m. Oct. 22, 2020 - Barrons.com
Gilead’s Sales Will Slip Even With Remdesivir Citigroup analyst Mohit Bansal rates Gilead stock at Buy but lowered his target price to $75 from $80. He sees two more years of revenue decline.
1:30 a.m. Oct. 20, 2020 - Barrons.com
Gilead Defends Its Covid Treatment After WHO Study Finds It Ineffective Gilead has criticized the WHO study findings and is seeking FDA approval for its antiviral remdesivir.
1:22 p.m. Oct. 16, 2020 - Barrons.com
Praxis Precision Pops 62% as Biotech IPO Party Continues A dozen biotech companies have gone public this month, including four that listed on Friday.
7:32 a.m. Oct. 12, 2020 - Barrons.com
It Takes More Than Good Science to Defeat a Disease. Just Look at the Nobel Prize. The Nobel in medicine was awarded for the discovery of the hepatitis C virus. The disease could be eliminated. Instead we’re treading water.
2:22 a.m. Oct. 12, 2020 - MarketWatch.com
Two Americans win Nobel prize in economics for auction theory advancesAmericans Paul R. Milgrom and Robert B. Wilson have won the Nobel Prize in economics for “improvements to auction theory and inventions of new auction formats.”
1:13 a.m. Oct. 9, 2020 - MarketWatch.com
World Food Program wins 2020 Nobel Peace PrizeThe Nobel Committee said that the coronavirus pandemic has added to the hunger faced by millions of people around the world and called on governments to ensure that WFP and other aid organizations receive the financial support necessary to feed them.
3:32 a.m. Oct. 5, 2020 - MarketWatch.com
3 win Nobel medicine award for hepatitis C virus discoveryAmericans Harvey J. Alter and Charles M. Rice, and British scientist Michael Houghton were awarded the Nobel Prize for Medicine or Physiology on Monday for the discovery of the hepatitis C virus.
7:04 a.m. Oct. 4, 2020 - By Jaimy Lee
Abbott exec: Why better COVID-19 tests may help the U.S. get back to normal John Hackett is a longtime executive at diagnostics company Abbott In less than seven months, Abbott Laboratories has introduced six COVID-19 tests, each a little different than the last, and that’s all part of the diagnostics company’s strategy to keep improving and enhancing tests that can detect current and past infections with the novel coronavirus.
5:13 a.m. Sept. 30, 2020 - Barrons.com
Regeneron’s Good News on Covid Antibodies Is Positive for Vaccines, Too Late Tuesday, the company showed that infusions of its antibody cocktail cleared the coronavirus and Covid-19 symptoms from a group of test subjects.
6:28 a.m. Sept. 14, 2020 - Barrons.com
Gilead Bets Heavily in a Cancer Biotech Acquisition Gilead is paying $21 billion for Immunomedics and its promising new cancer treatment. Wall Street’s unsure Gilead will earn back the steep acquisition price.
12:30 p.m. Sept. 13, 2020 - MarketWatch
Gilead reaches $21 billion deal for ImmunomedicsGilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of the cancer-drugs business. Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company.
12:29 p.m. Sept. 13, 2020 - MarketWatch
AstraZeneca COVID-19 vaccine trials resumeAstraZeneca PLC said Saturday clinical trials for its experimental coronavirus vaccine have resumed in the U.K. after regulators concluded it was safe to do so, following a pause in studies globally after a person who received the vaccine had an unexplained illness.
12:01 p.m. Sept. 12, 2020 - By Cara Lombardo
Gilead near deal to buy Immunomedics for more than $20 billion Biotech drugmaker has a market value of roughly $10 billionGilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.
Browse topics:
Link to MarketWatch's Slice.